{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:38:55Z","timestamp":1786358335518,"version":"build-2736575974"},"reference-count":83,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1097\/hjh.0b013e3280113950","type":"journal-article","created":{"date-parts":[[2006,11,30]],"date-time":"2006-11-30T04:02:34Z","timestamp":1164859354000},"page":"25-35","source":"Crossref","is-referenced-by-count":41,"title":["Novel therapies blocking the renin\u2013angiotensin\u2013aldosterone system in the management of hypertension and related disorders"],"prefix":"10.1097","volume":"25","author":[{"given":"Henry","family":"Krum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210208","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/08037050410033169","article-title":"Cardiovascular risk stratification according to the 2003 ESH\u2013ESC guidelines in uncomplicated patients with essential hypertension: comparison with the 1999 WHO\/ISH guidelines criteria","volume":"13","author":"Cuspidi","year":"2004","journal-title":"Blood Press"},{"key":"R2-4-20210208","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.hjh.0000165623.72310.dd","article-title":"The cardiovascular continuum and renin\u2013angiotensin\u2013aldosterone system blockade","volume":"23","author":"Dzau","year":"2005","journal-title":"J Hypertens Suppl"},{"key":"R3-4-20210208","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pbiomolbio.2005.05.011","article-title":"ACE2: A novel therapeutic target for cardiovascular diseases","volume":"91","author":"Der Sarkissian","year":"2006","journal-title":"Prog Biophys Mol Biol"},{"key":"R4-4-20210208","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0002-8703(82)90278-2","article-title":"Prediction of sustained antihypertensive efficacy of chronic captopril therapy: relationships to immediate blood pressure response and control plasma renin activity","volume":"103","author":"Waeber","year":"1982","journal-title":"Am Heart J"},{"key":"R5-4-20210208","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/08037050500230227","article-title":"Angiotensin receptor blockers: therapeutic targets and cardiovascular protection","volume":"14","author":"Ruilope","year":"2005","journal-title":"Blood Press"},{"key":"R6-4-20210208","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1592\/phco.22.13.1173.33517","article-title":"Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema","volume":"22","author":"Abdi","year":"2002","journal-title":"Pharmacotherapy"},{"key":"R7-4-20210208","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11906-004-0069-6","article-title":"Aldosterone and aldosterone antagonism in systemic hypertension","volume":"6","author":"Frishman","year":"2004","journal-title":"Curr Hypertens Rep"},{"key":"R8-4-20210208","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2003.10.008","article-title":"The 45-year story of the development of an anti-aldosterone more specific than spironolactone","volume":"217","author":"Menard","year":"2004","journal-title":"Mol Cell Endocrinol"},{"issue":"Suppl. 6B","key":"R9-4-20210208","first-page":"24S","article-title":"Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system endogenous antagonists","volume":"87","author":"Johnston","year":"1989","journal-title":"Am J Med"},{"key":"R10-4-20210208","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0024-3205(90)90208-9","article-title":"Degradation and clearance of atrial natriuretic factors (ANF)","volume":"47","author":"Gerbes","year":"1990","journal-title":"Life Sci"},{"key":"R11-4-20210208","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/01.HYP.0000030178.90322.11","article-title":"Renal hemodynamic and natriuretic effects of concomitant angiotensin-converting enzyme and neutral endopeptidase inhibition in men","volume":"40","author":"Regamey","year":"2002","journal-title":"Hypertension"},{"key":"R12-4-20210208","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(01)06584-9","article-title":"Vasopeptidase inhibitors","volume":"358","author":"Weber","year":"2001","journal-title":"Lancet"},{"key":"R13-4-20210208","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1161\/hc4001.097191","article-title":"Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?","volume":"104","author":"Corti","year":"2001","journal-title":"Circulation"},{"key":"R14-4-20210208","first-page":"1414","article-title":"Omapatrilat Bristol-Myers Squibb","volume":"2","author":"Tabrizchi","year":"2001","journal-title":"Curr Opin Invest Drugs"},{"key":"R15-4-20210208","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"issue":"Suppl.","key":"R16-4-20210208","first-page":"119","article-title":"The renin\u2013angiotensin system and vascular function The role of angiotensin II, angiotensin-converting enzyme, and alternative conversion of angiotensin I","volume":"12","author":"Roks","year":"1997","journal-title":"Heart Vessels"},{"key":"R17-4-20210208","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1161\/01.CIR.96.9.3072","article-title":"Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats","volume":"96","author":"Menard","year":"1997","journal-title":"Circulation"},{"key":"R18-4-20210208","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1172\/JCI117251","article-title":"Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells","volume":"93","author":"Kagami","year":"1994","journal-title":"J Clin Invest"},{"key":"R19-4-20210208","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI0214276","article-title":"Pivotal role of the renin\/prorenin receptor in angiotensin II production and cellular responses to renin","volume":"109","author":"Nguyen","year":"2002","journal-title":"J Clin Invest"},{"key":"R20-4-20210208","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.ki.5000079","article-title":"Receptor-mediated actions of renin and prorenin","volume":"69","author":"Oliver","year":"2006","journal-title":"Kidney Int"},{"key":"R21-4-20210208","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.ki.5000011","article-title":"Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms","volume":"69","author":"Huang","year":"2006","journal-title":"Kidney Int"},{"key":"R22-4-20210208","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00041552-200301000-00009","article-title":"The renin receptor: the facts, the promise and the hope","volume":"12","author":"Nguyen","year":"2003","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R23-4-20210208","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/j.1552-4604.1994.tb04000.x","article-title":"Renin inhibition: a new approach to cardiovascular therapy","volume":"34","author":"Frishman","year":"1994","journal-title":"J Clin Pharmacol"},{"key":"R24-4-20210208","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0006-291X(03)01451-7","article-title":"Structure-based design of aliskiren, a novel orally effective renin inhibitor","volume":"308","author":"Wood","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"R25-4-20210208","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.HYP.0000179573.91016.3f","article-title":"Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats","volume":"46","author":"Pilz","year":"2005","journal-title":"Hypertension"},{"key":"R26-4-20210208","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hy0102.102293","article-title":"Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril","volume":"39","author":"Nussberger","year":"2002","journal-title":"Hypertension"},{"key":"R27-4-20210208","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","article-title":"Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients","volume":"111","author":"Gradman","year":"2005","journal-title":"Circulation"},{"key":"R28-4-20210208","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.HYP.0000101688.17370.87","article-title":"Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren","volume":"42","author":"Stanton","year":"2003","journal-title":"Hypertension"},{"key":"R30-4-20210208","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/BF02158515","article-title":"Konstitution des aldosterons, des neuen mineralocorticoids","volume":"10","author":"Simpson","year":"1954","journal-title":"Experienta"},{"key":"R31-4-20210208","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2165\/00003495-200262050-00001","article-title":"Rationale for the use of aldosterone antagonists in congestive heart failure","volume":"62","author":"Rocha","year":"2002","journal-title":"Drugs"},{"issue":"Suppl. O","key":"R32-4-20210208","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/eurheartj\/16.suppl_O.107","article-title":"The renin\u2013angiotensin\u2013aldosterone system and myocardial collagen matrix remodeling in congestive heart failure","volume":"16","author":"Brilla","year":"1995","journal-title":"Eur Heart J"},{"key":"R33-4-20210208","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/01.HYP.29.1.45","article-title":"Vascular aldosterone in genetically hypertensive rats","volume":"29","author":"Takeda","year":"1997","journal-title":"Hypertension"},{"key":"R34-4-20210208","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","article-title":"Pathological hypertrophy and cardiac interstitium. Fibrosis and renin\u2013angiotensin\u2013aldosterone system","volume":"83","author":"Weber","year":"1991","journal-title":"Circulation"},{"key":"R35-4-20210208","first-page":"E657","article-title":"Determinants of cardiac fibrosis in experimental hypermineralocorticoid states","volume":"269","author":"Young","year":"1995","journal-title":"Am J Physiol"},{"key":"R36-4-20210208","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1161\/01.HYP.26.6.971","article-title":"Biological determinants of aldosterone-induced cardiac fibrosis in rats","volume":"26","author":"Robert","year":"1995","journal-title":"Hypertension"},{"key":"R37-4-20210208","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"15","author":"Greene","year":"1996","journal-title":"J Clin Invest"},{"key":"R38-4-20210208","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.mce.2003.10.047","article-title":"Aldosterone target organ protection by eplerenone","volume":"217","author":"Rudolph","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"R39-4-20210208","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R40-4-20210208","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1046\/j.1523-1755.2000.00983.x","article-title":"Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology","volume":"57","author":"Delyani","year":"2000","journal-title":"Kidney Int"},{"key":"R41-4-20210208","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"R42-4-20210208","doi-asserted-by":"crossref","first-page":"A24","DOI":"10.1016\/S0895-7061(02)02333-6","article-title":"Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination therapy in diabetic hypertensives with microalbuminuria","volume":"15","author":"Epstein","year":"2002","journal-title":"Am J Hypertens"},{"issue":"Suppl. 1","key":"R43-4-20210208","doi-asserted-by":"crossref","first-page":"A24","DOI":"10.1016\/S0895-7061(02)02334-8","article-title":"Comparison of eplerenone and losartan in patients with low-renin hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"R44-4-20210208","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin\u2013angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"R45-4-20210208","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1177\/0091270003258189","article-title":"Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?","volume":"43","author":"Prisant","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"R46-4-20210208","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","article-title":"Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension","volume":"93","author":"Williams","year":"2004","journal-title":"Am J Cardiol"},{"key":"R47-4-20210208","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","article-title":"Effects of eplerenone versus losartan in patients with low-renin hypertension","volume":"150","author":"Weinberger","year":"2005","journal-title":"Am Heart J"},{"key":"R48-4-20210208","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","article-title":"Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension","volume":"41","author":"White","year":"2003","journal-title":"Hypertension"},{"key":"R49-4-20210208","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9149(03)00461-2","article-title":"Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension","volume":"92","author":"White","year":"2003","journal-title":"Am J Cardiol"},{"key":"R50-4-20210208","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","article-title":"Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients","volume":"41","author":"Flack","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R51-4-20210208","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10741-005-2343-3","article-title":"Aldosterone biosynthesis, regulation, and classical mechanism of action","volume":"10","author":"Williams","year":"2005","journal-title":"Heart Fail Rev"},{"key":"R52-4-20210208","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.mce.2003.10.022","article-title":"Aldosterone-synthase overexpression in heart: a tool to explore aldosterone's effects","volume":"217","author":"Heymes","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"R53-4-20210208","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/01.RES.73.3.413","article-title":"Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype","volume":"73","author":"Sadoshima","year":"1993","journal-title":"Circ Res"},{"key":"R54-4-20210208","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ki.1996.82","article-title":"Vasoactive hormones and renal sclerosis","volume":"49","author":"Egido","year":"1996","journal-title":"Kidney Int"},{"key":"R55-4-20210208","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/01.RES.62.4.749","article-title":"Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells","volume":"62","author":"Geisterfer","year":"1988","journal-title":"Circ Res"},{"key":"R56-4-20210208","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1681\/ASN.V781207","article-title":"Captopril reverses high-glucose-induced growth effects on LLC-PK1 cells partly by decreasing transforming growth factor-beta receptor protein expressions","volume":"7","author":"Guh","year":"1996","journal-title":"J Am Soc Nephrol"},{"issue":"5 Suppl.","key":"R57-4-20210208","first-page":"S7","article-title":"The renin\u2013angiotensin system and extracellular matrix","volume":"71","author":"Hahn","year":"1993","journal-title":"Clin Invest"},{"issue":"Suppl.","key":"R58-4-20210208","first-page":"S51","article-title":"Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis","volume":"12","author":"Ruiz-Ortega","year":"1994","journal-title":"J Hypertens"},{"key":"R59-4-20210208","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1161\/01.RES.82.12.1338","article-title":"Angiotensin II type 1 receptor-induced extracellular signal-regulated protein kinase activation is mediated by Ca2+\/calmodulin-dependent transactivation of epidermal growth factor receptor","volume":"82","author":"Murasawa","year":"1998","journal-title":"Circ Res"},{"key":"R60-4-20210208","doi-asserted-by":"crossref","first-page":"8890","DOI":"10.1074\/jbc.273.15.8890","article-title":"Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells","volume":"273","author":"Eguchi","year":"1998","journal-title":"J Biol Chem"},{"key":"R61-4-20210208","doi-asserted-by":"crossref","first-page":"15926","DOI":"10.1074\/jbc.M909616199","article-title":"Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor key role for the adaptor protein Shc","volume":"275","author":"Heeneman","year":"2000","journal-title":"J Biol Chem"},{"key":"R62-4-20210208","doi-asserted-by":"crossref","first-page":"12563","DOI":"10.1074\/jbc.270.21.12563","article-title":"Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells","volume":"270","author":"Linseman","year":"1995","journal-title":"J Biol Chem"},{"key":"R63-4-20210208","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/nm1275","article-title":"Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach","volume":"11","author":"Lautrette","year":"2005","journal-title":"Nat Med"},{"key":"R64-4-20210208","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1093\/ndt\/gfi143","article-title":"\u201cAs time goes by\u201d: angiotensin II-mediated transactivation of the EGF receptor comes of age","volume":"20","author":"Wolf","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"R65-4-20210208","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/j.1523-1755.2004.00955.x","article-title":"Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes","volume":"66","author":"Wassef","year":"2004","journal-title":"Kidney Int"},{"key":"R66-4-20210208","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/01.HYP.0000058701.11991.C4","article-title":"Pressure-induced activation of extracellular signal-regulated kinase 1\/2 in small arteries","volume":"41","author":"Eskildsen-Helmond","year":"2003","journal-title":"Hypertension"},{"key":"R67-4-20210208","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/01.HYP.0000132883.20764.12","article-title":"Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo","volume":"44","author":"Kelly","year":"2004","journal-title":"Hypertension"},{"key":"R68-4-20210208","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1172\/JCI200320087","article-title":"What brings pericytes to tumor vessels?","volume":"112","author":"Jain","year":"2003","journal-title":"J Clin Invest"},{"key":"R69-4-20210208","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"R70-4-20210208","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u20139","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res"},{"key":"R71-4-20210208","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nm0805-821","article-title":"Good ACE, bad ACE do battle in lung injury, SARS","volume":"11","author":"Nicholls","year":"2005","journal-title":"Nat Med"},{"key":"R72-4-20210208","doi-asserted-by":"crossref","first-page":"14838","DOI":"10.1074\/jbc.M200581200","article-title":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase","volume":"277","author":"Vickers","year":"2002","journal-title":"J Biol Chem"},{"key":"R73-4-20210208","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"key":"R74-4-20210208","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1152\/physiolgenomics.00227.2003","article-title":"Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats","volume":"17","author":"Santos","year":"2004","journal-title":"Physiol Genom"},{"key":"R75-4-20210208","doi-asserted-by":"crossref","first-page":"15532","DOI":"10.1074\/jbc.M212934200","article-title":"Novel peptide inhibitors of angiotensin-converting enzyme 2","volume":"278","author":"Huang","year":"2003","journal-title":"J Biol Chem"},{"key":"R76-4-20210208","doi-asserted-by":"crossref","first-page":"11852","DOI":"10.1021\/ja0277226","article-title":"Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors","volume":"124","author":"Dales","year":"2002","journal-title":"J Am Chem Soc"},{"key":"R77-4-20210208","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"R78-4-20210208","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1113\/expphysiol.2005.031096","article-title":"Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats","volume":"90","author":"Huentelman","year":"2005","journal-title":"Exp Physiol"},{"key":"R79-4-20210208","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/01.HYP.0000196685.91424.01","article-title":"Potential of gene therapy strategy for the treatment of hypertension","volume":"47","author":"Raizada","year":"2006","journal-title":"Hypertension"},{"key":"R80-4-20210208","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1161\/01.HYP.0000171587.44736.ba","article-title":"Differential effects of angiotensin II type-1 receptor antisense oligonucleotides on renal function in spontaneously hypertensive rats","volume":"46","author":"Yoneda","year":"2005","journal-title":"Hypertension"},{"key":"R81-4-20210208","doi-asserted-by":"crossref","first-page":"R619","DOI":"10.1152\/ajpregu.00140.2004","article-title":"Antisense oligodeoxynucleotides directed against a novel angiotensinogen mRNA-stabilizing protein reduce blood pressure in spontaneously hypertensive rats","volume":"287","author":"Klett","year":"2004","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R82-4-20210208","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1097\/00004872-198904002-00014","article-title":"Immunological approach to blockade of the renin-substrate reaction","volume":"7","author":"Michel","year":"1989","journal-title":"J Hypertens Suppl"},{"key":"R83-4-20210208","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1042\/CS20030381","article-title":"Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects","volume":"107","author":"Brown","year":"2004","journal-title":"Clin Sci (Lond)"},{"key":"R84-4-20210208","first-page":"107","article-title":"Target organ protection from a novel angiotensin II receptor (AT1) vaccine ATR12181 in spontaneously hypertensive rats","volume":"3","author":"Zhu","year":"2006","journal-title":"Cell Mol Immunol"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004872-200701000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:07:02Z","timestamp":1786032422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004872-200701000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e3280113950","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}